Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 495

1.

Novel approaches on epigenetics.

Papait R, Monti E, Bonapace IM.

Curr Opin Drug Discov Devel. 2009 Mar;12(2):264-75. Review.

PMID:
19333872
2.

Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.

Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, CalabrĂ² L, Maio M.

J Cell Physiol. 2007 Aug;212(2):330-44. Review.

PMID:
17458893
3.

Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.

Santini V, Gozzini A, Ferrari G.

Curr Drug Metab. 2007 May;8(4):383-93. Review.

PMID:
17504226
4.

Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.

Mai A, Altucci L.

Int J Biochem Cell Biol. 2009 Jan;41(1):199-213. doi: 10.1016/j.biocel.2008.08.020. Epub 2008 Aug 22. Review.

PMID:
18790076
5.

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.

Bishton M, Kenealy M, Johnstone R, Rasheed W, Prince HM.

Expert Rev Anticancer Ther. 2007 Oct;7(10):1439-49. Review.

PMID:
17944568
6.

Histone deacetylation in epigenetics: an attractive target for anticancer therapy.

Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R, Simeoni S, Ragno R.

Med Res Rev. 2005 May;25(3):261-309. Review.

PMID:
15717297
7.
8.

Epigenetic drugs take on cancer.

Kaiser J.

Science. 2010 Oct 29;330(6004):576-8. doi: 10.1126/science.330.6004.576. No abstract available.

PMID:
21030620
9.
10.

Epigenetic alterations and cancer: new targets for therapy.

Allen A.

IDrugs. 2007 Oct;10(10):709-12. Review.

PMID:
17899489
11.
12.

Epigenetic transitions: towards therapeutic targets.

Kalebic T.

Expert Opin Ther Targets. 2003 Dec;7(6):693-9.

PMID:
14640906
13.

New therapeutic targets in cancer: the epigenetic connection.

Herranz M, Esteller M.

Clin Transl Oncol. 2006 Apr;8(4):242-9. Review.

PMID:
16648099
14.

Chromatin as a target for the DNA-binding anticancer drugs.

Majumder P, Pradhan SK, Devi PG, Pal S, Dasgupta D.

Subcell Biochem. 2007;41:145-89. Review.

PMID:
17484128
15.

Epigenetic regulation of gene expression as an anticancer drug target.

Ferguson LR, Tatham AL, Lin Z, Denny WA.

Curr Cancer Drug Targets. 2011 Feb;11(2):199-212.

PMID:
21158714
16.

The dynamic epigenome and its implications in toxicology.

Szyf M.

Toxicol Sci. 2007 Nov;100(1):7-23. Epub 2007 Aug 3. Review.

17.

Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis.

Vogiatzi P, Vindigni C, Roviello F, Renieri A, Giordano A.

J Cell Physiol. 2007 May;211(2):287-95. Review.

PMID:
17238139
18.

Future directions for the use of hypomethylating agents.

Garcia-Manero G, Gore SD.

Semin Hematol. 2005 Jul;42(3 Suppl 2):S50-9. Review.

PMID:
16015506
19.

Small molecule modulators in epigenetics: implications in gene expression and therapeutics.

Swaminathan V, Reddy BA, Ruthrotha Selvi B, Sukanya MS, Kundu TK.

Subcell Biochem. 2007;41:397-428. Review.

PMID:
17484138
20.

Epigenetic tools in potential anticancer therapy.

Sebova K, Fridrichova I.

Anticancer Drugs. 2010 Jul;21(6):565-77. doi: 10.1097/CAD.0b013e32833a4352. Review.

PMID:
20436342
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk